Nick Leschly, 2seventy bio CEO (Jeff Rumans)
March 16, 2022 09:50 AM EDT
Financing
Bioregnum

With its share price chewed to pieces, Nick Leschly's 2sev­en­ty scores $170M to help weath­er the storm

John Carroll

Editor & Founder

A lit­tle more than a week af­ter blue­bird’s CFO an­nounced a quick ex­it as the com­pa­ny flagged an alarm about its abil­i­ty to sur­vive, the …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

Judge halts some NIH cuts af­ter 22 states sue

Ver­tex op­er­a­tions chief Stu­art Ar­buck­le to re­tire

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times